NEW YORK – BioMarin has chosen PerkinElmer to provide testing in support of the biopharmaceutical firm's sponsored testing program for patients in Mexico, PerkinElmer said on Wednesday.
Specifically, the testing program is aimed at Batten disease and mucopolysaccharidosis (MPS) disorders and is designed to help patients and clinicians by providing tests for identifying MPS IVA, also called Morquio A syndrome; MPS VI, or Maroteaux-Lamy syndrome; and CLN2, or late infantile neuronal ceroid lipofuscinosis type 2 disease.
PerkinElmer will provide biochemical and genetic testing to patients in Mexico suspected of having Batten disease or an MPS condition, with funding provided by BioMarin. Patients in San Rafael, California-based BioMarin's testing program will receive biochemical screening, followed by confirmatory genetic testing as necessary. All testing will use dried blood spots, Waltham, Massachusetts-based PerkinElmer said.
Financial and other terms of the agreement were not disclosed.